[1] Bozoky Z, Balogh L, Mathe D, et al. Preparation and investigation of 99m technetium-labeled low-density lipoproteins in rabbits with experimentally induced hypercholesterolemia. Eur Biophys J,2004, 33(2):140-145.
[2] Torzewski M, Shaw PX, Han KR, et al. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization.Atheroseler Thromb Vasc Biol, 2004, 24(12):2307-2312.
[3] Tsimikas S. Noninvasive imaging of oxidized low-density lipoprotein in atherosclerotic plaques with tagged oxidation-specific antibodies. Am J Cardiol, 2002, 90(10C):22L-27L.
[4] Dinkelborg LM, Duda SH, Hanke H, et al. Molecular imaging of atherosclerosis using a technetium-99m-labeled endothelin derivative. J Nucl Med, 1998, 39(10):1819-1822.
[5]
[6] Narula J, Petrov A, Bianchi C, et al. Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F (ab')2 specifie for the proliferating smooth muscle cells of human atheroma. Circulation, 1995, 92(3):474-484.
[7] Mitchel J, Waters D, Lai T, et al. Identification of coronary thrombus with a Ⅱb/Ⅲa platelet inhibitor radiophannaceutical,technetium-99m DMP-444:A canine model. Circulation, 2000,101(14):1643-1646.
[8] 曹卫,张永学,安锐.99mTc-Ap4A显像探测动脉粥样硬化斑块的动物实验研究.中华核医学杂志,2001,21(6):325-328.
[9] Lederman RJ, Raylman RR, Fisher SJ, et al. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeo-xyglucose(FDG). Nucl Med Commun, 2001, 22(7):747-753.
[10] Ogawa M, Ishino S, Mukai T, et al. (18)F-FDG accumulation in atherosclerotic plaques:immunohistochemical and PET imaging study. J Nucl Med, 2004, 45(7):1245-1250.
[11] Tawakol A, Migrino RQ, Hoffmann U, et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol, 2005, 12(3):294-301.
[12] Kolodgie FD, Petrov A, Virmani R, et al. Targeting of apoptotic macrop-hages and experimental atheroma with radiolabeled annexin V. Circulation, 2003, 108(25):3134-3139.
[13] Matter CM, Schuler PK, Alessi P, et al. Molecular imaging of atherosclerotic plaques using a human antibody against the extradomain B of fibronectin. Am Heart Assoc, Circ Res, 2004, 95(12):1225-1233.
[14] Gawaz M, Konrad I, Hauer AI, et al. Non-invasive imaging of glycoprotein Ⅵ binding to injured arterial lesions. Thromb Heamost, 2005, 93(5):910-913.
[15] Qin G, Zhang Y, Cao W, et al. Molecular imaging of atherosclerotic plaques with technetium-99m labelled antisense oligonucleotides. Eur J Nucl Med Mol Imaging, 2005, 32(1):6-14.
[16] Amnovazzi A, Bonanno E, Arca M, et al. 99mTc-intedeukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. Eur J Nucl Med Mol Imaging, 2006, 33(2):117-126.